REFERENCES
- Scandanavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389, [CSA]
- Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 1995; 333: 1301–1307, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sacks F. M., Pfeffer M. A., Moye L. A., Rouleau J. L., Rutherford J. D., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 1996; 335: 1001–1009, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998; 339: 1349–1357, [CROSSREF], [CSA]
- Downs J. R., Clearfield M., Weis S., Whitney E., Shapiro D. R., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–1622, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998–3007, [CROSSREF], [CSA]
- Shepherd J., Blauw G. J., Murphy M. B., Bollen E. L., Buckley B. M., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–1630, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22, [CROSSREF], [CSA]
- Werner N., Nickenig G., Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res. Cardiol. 2002; 97: 105–116, [INFOTRIEVE], [CROSSREF], [CSA]
- Wierzbicki A. S., Poston R., Ferro A. The lipid and non-lipid effects of statins. Pharmacol. Ther. 2003; 99: 95–112, [INFOTRIEVE], [CROSSREF], [CSA]
- Etminan M., Gill S., Samii A. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy 2003; 23: 726–730, [INFOTRIEVE], [CROSSREF], [CSA]
- Bauer D. C., Mundy G. R., Jamal S. A., Black D. M., Cauley J. A., et al. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch. Intern. Med. 2004; 164: 146–152, [INFOTRIEVE], [CROSSREF], [CSA]
- Vollmer T., Key L., Durkalski V., Tyor W., Corboy J., et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607–1608, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Neuhaus O., Stuve O., Zamvil S. S., Hartung H. P. Are statins a treatment option for multiple sclerosis?. Lancet Neurol. 2004; 3: 369–371, [INFOTRIEVE], [CROSSREF], [CSA]
- Chan K. K., Oza A. M., Siu L. L. The statins as anticancer agents. Clin. Cancer Res. 2003; 9: 10–19, [INFOTRIEVE], [CSA]
- Jakobisiak M., Golab J. Potential antitumor effects of statins. Int. J. Oncol. 2003; 23: 1055–1069, [INFOTRIEVE], [CSA]
- Newman T. B., Hulley S. B. Carcinogenicity of lipid-lowering drugs. JAMA 1996; 275: 55–60, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Duncan R. E., El Sohemy A., Archer M. C. Statins and cancer development. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 1897–1898, [INFOTRIEVE], [CROSSREF], [CSA]
- Graaf M. R., Richel D. J., van Noorden C. J., Guchelaar H. J. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat. Rev. 2004; 30: 609–641, [INFOTRIEVE], [CROSSREF], [CSA]
- The LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002; 359: 1379–1387, [CROSSREF], [CSA]
- Strandberg T. E., Pyorala K., Cook T. J., Wilhelmsen L., Faergeman O., et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364: 771–777, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Olsen J. H., Johansen C., Sørensen H. T., McLaughlin J. K., Mellemkjaer L., et al. Lipid-lowering medication and risk of cancer. J. Clin. Epidemiol. 1999; 52: 167–169, [INFOTRIEVE], [CROSSREF], [CSA]
- Blais L., Desgagne A., LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch. Intern. Med. 2000; 160: 2363–2368, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kaye J. A., Meier C. R., Walker A. M., Jick H. Statin use, hyperlipidaemia, and the risk of breast cancer. Br. J. Cancer 2002; 86: 1436–1439, [INFOTRIEVE], [CROSSREF], [CSA]
- Coogan P. F., Rosenberg L., Palmer J. R., Strom B. L., Zauber A. G., et al. Statin use and the risk of breast and prostate cancer. Epidemiology 2002; 13: 262–267, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Beck P., Wysowski D. K., Downey W., Butler-Jones D. Statin use and the risk of breast cancer. J. Clin. Epidemiol. 2003; 56: 280–285, [INFOTRIEVE], [CROSSREF], [CSA]
- Cauley J. A., Zmuda J. M., Lui L. Y., Hillier T. A., Ness R. B., et al. Lipid-lowering drug use and breast cancer in older women: a prospective study. J. Womens Health 2003; 12: 749–756, [CROSSREF], [CSA]
- Kaye J. A., Jick H. Statin use and cancer risk in the General Practice Research Database. Br. J. Cancer 2004; 90: 635–637, [INFOTRIEVE], [CROSSREF], [CSA]
- Boudreau D. M., Gardner J. S., Malone K. E., Heckbert S. R., Blough D. K., et al. The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women. Cancer 2004; 100: 2308–2316, [INFOTRIEVE], [CROSSREF], [CSA]
- Zhang Y., Holford T. R., Leaderer B., Zahm S. H., Boyle P., et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004; 15: 419–428, [INFOTRIEVE], [CROSSREF], [CSA]
- Graaf M. R., Beiderbeck A. B., Egberts A. C., Richel D. J., Guchelaar H. J. The risk of cancer in users of statins. J. Clin. Oncol. 2004; 22: 2388–2394, [INFOTRIEVE], [CROSSREF], [CSA]
- Friis S., Poulsen A. H., Johnsen S. P., McLaughlin J. K., Fryzek J. P., et al. Cancer risk among statin users: a population-based cohort study. Int. J. Cancer 2005; 114: 643–647, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Poynter J. N., Gruber S. B., Higgins P. D., Almog R., Bonner J. D., et al. Statins and the risk of colorectal cancer. N. Engl. J. Med. 2005; 352: 2184–2192, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Shannon J., Tewoderos S., Garzotto M., Beer T. M., Derenick R., et al. Statins and prostate cancer risk: a case-control study. Am. J. Epidemiol 2005; 162: 318–325, [INFOTRIEVE], [CROSSREF], [CSA]
- Katz M. S., Minsky B. D., Saltz L. B., Riedel E., Chessin D. B., et al. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2005; 62: 1363–1370, [INFOTRIEVE], [CROSSREF], [CSA]
- Sleijfer S., van der G. A., Planting A. S., Stoter G., Verweij J. The potential of statins as part of anti-cancer treatment. Eur. J. Cancer 2005; 41: 516–522, [INFOTRIEVE], [CROSSREF], [CSA]
- Katz M. S. Therapy insight: potential of statins for cancer chemoprevention and therapy. Nat. Clin. Pract. Oncol. 2005; 2: 82–89, [INFOTRIEVE], [CROSSREF], [CSA]
- Stamm J. A., Ornstein D. L. The role of statins in cancer prevention and treatment. Oncology 2005; 19: 739–750, [INFOTRIEVE], [CSA]
- Bellosta S., Paoletti R., Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109: III50–III57, [INFOTRIEVE], [CROSSREF], [CSA]
- Bellosta S., Ferri N., Bernini F., Paoletti R., Corsini A. Non-lipid-related effects of statins. Ann. Med. 2000; 32: 164–176, [INFOTRIEVE], [CSA]
- Thompson P. D., Clarkson P., Karas R. H. Statin-associated myopathy. JAMA 2003; 289: 1681–1690, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gaist D., Jeppesen U., Andersen M., Garcia Rodriguez L. A., Hallas J., et al. Statins and risk of polyneuropathy: a case-control study. Neurology 2002; 58: 1333–1337, [PUBMED], [INFOTRIEVE], [CSA]
- McKenney J. M. Pharmacologic characteristics of statins. Clin. Cardiol. 2003; 26: III32–III38, [INFOTRIEVE], [CSA]
- Maron D. J., Fazio S., Linton M. F. Current perspectives on statins. Circulation 2000; 101: 207–213, [INFOTRIEVE], [CSA]
- Goldstein J. L., Brown M. S. Regulation of the mevalonate pathway. Nature 1990; 343: 425–430, [INFOTRIEVE], [CROSSREF], [CSA]
- Takemoto M., Liao J. K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 2001; 21: 1712–1719, [INFOTRIEVE], [CSA]
- Singh R. P., Kumar R., Kapur N. Molecular regulation of cholesterol biosynthesis: implications in carcinogenesis. J. Environ. Pathol. Toxicol. Oncol. 2003; 22: 75–92, [INFOTRIEVE], [CROSSREF], [CSA]
- Sinensky M. Recent advances in the study of prenylated proteins. Biochim. Biophys. Acta 2000; 1484: 93–106, [INFOTRIEVE], [CSA]
- Caraglia M., Budillon A., Tagliaferri P., Marra M., Abbruzzese A., et al. Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. Curr. Drug Targets 2005; 6: 301–323, [INFOTRIEVE], [CROSSREF], [CSA]
- Bos J. L. Ras oncogenes in human cancer: a review. Cancer Res. 1989; 49: 4682–4689, [INFOTRIEVE], [CSA]
- Denoyelle C., Vasse M., Korner M., Mishal Z., Ganne F., et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001; 22: 1139–1148, [INFOTRIEVE], [CSA]
- Adjei A. A. Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer Inst. 2001; 93: 1062–1074, [PUBMED], [INFOTRIEVE], [CSA]
- Xia Z., Tan M. M., Wong W. W., Dimitroulakos J., Minden M. D., et al. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 2001; 15: 1398–1407, [INFOTRIEVE], [CROSSREF], [CSA]
- Kusama T., Mukai M., Iwasaki T., Tatsuta M., Matsumoto Y., et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Cancer Res. 2001; 61: 4885–4891, [INFOTRIEVE], [CSA]
- van de Donk N. W., Lokhorst H. M., Nijhuis E. H., Kamphuis M. M., Bloem A. C. Geranylgeranylated proteins are involved in the regulation of myeloma cell growth. Clin. Cancer Res. 2005; 11: 429–439, [INFOTRIEVE], [CSA]
- Siperstein M. D. Cholesterol, cholesterogenesis and cancer. Adv. Exp. Med. Biol. 1995; 369: 155–166, [INFOTRIEVE], [CSA]
- McCarty M. F. Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-I down-regulation. Med. Hypotheses 2001; 56: 12–16, [INFOTRIEVE], [CROSSREF], [CSA]
- Wachtershauser A., Akoglu B., Stein J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 2001; 22: 1061–1067, [INFOTRIEVE], [CROSSREF], [CSA]
- Rao S., Porter D. C., Chen X., Herliczek T., Lowe M., et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc. Natl. Acad. Sci. U.S.A. 1999; 96: 7797–7802, [INFOTRIEVE], [CROSSREF], [CSA]
- Park C., Lee I., Kang W. K. Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. Carcinogenesis 2001; 22: 1727–1731, [INFOTRIEVE], [CROSSREF], [CSA]
- Brower V. Of cancer and cholesterol: studies elucidate anticancer mechanisms of statins. J. Natl. Cancer Inst. 2003; 95: 844–846, [INFOTRIEVE], [CSA]
- Dalen J. E., Dalton W. S. Does lowering cholesterol cause cancer?. JAMA 1996; 275: 67–69, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Narisawa T., Morotomi M., Fukaura Y., Hasebe M., Ito M., et al. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn. J. Cancer Res. 1996; 87: 798–804, [INFOTRIEVE], [CSA]
- Marcelli M., Cunningham G. R., Haidacher S. J., Padayatty S. J., Sturgis L., et al. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res. 1998; 58: 76–83, [INFOTRIEVE], [CSA]
- Alonso D. F., Farina H. G., Skilton G., Gabri M. R., De Lorenzo M. S., et al. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res. Treat. 1998; 50: 83–93, [INFOTRIEVE], [CROSSREF], [CSA]
- Rubins J. B., Greatens T., Kratzke R. A., Tan A. T., Polunovsky V. A., et al. Lovastatin induces apoptosis in malignant mesothelioma cells. Am. J. Respir. Crit. Care Med. 1998; 157: 1616–1622, [INFOTRIEVE], [CSA]
- Crick D. C., Andres D. A., Danesi R., Macchia M., Waechter C. J. Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells. J. Neurochem. 1998; 70: 2397–2405, [INFOTRIEVE], [CSA]
- Lee S. J., Ha M. J., Lee J., Nguyen P., Choi Y. H., et al. Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells. J. Biol. Chem. 1998; 273: 10618–10623, [INFOTRIEVE], [CROSSREF], [CSA]
- Ghosh P. M., Ghosh-Choudhury N., Moyer M. L., Mott G. E., Thomas C. A., et al. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Oncogene 1999; 18: 4120–4130, [INFOTRIEVE], [CROSSREF], [CSA]
- Choi J. W., Jung S. E. Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells. J. Pharmacol. Exp. Ther. 1999; 289: 572–579, [INFOTRIEVE], [CSA]
- Dimitroulakos J., Nohynek D., Backway K. L., Hedley D. W., Yeger H., et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood 1999; 93: 1308–1318, [INFOTRIEVE], [CSA]
- Macaulay R. J., Wang W., Dimitroulakos J., Becker L. E., Yeger H. Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro. J. Neurooncol. 1999; 42: 1–11, [INFOTRIEVE], [CROSSREF], [CSA]
- Weiss R. H., Ramirez A., Joo A. Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and P13 kinase. J. Am. Soc. Nephrol. 1999; 10: 1880–1890, [INFOTRIEVE], [CSA]
- Wang W., Macaulay R. J. Mevalonate prevents lovastatin-induced apoptosis in medulloblastoma cell lines. Can. J. Neurol. Sci. 1999; 26: 305–310, [INFOTRIEVE], [CSA]
- Matar P., Rozados V. R., Binda M. M., Roggero E. A., Bonfil R. D., et al. Inhibitory effect of lovastatin on spontaneous metastases derived from a rat lymphoma. Clin. Exp. Metastasis 1999; 17: 19–25, [INFOTRIEVE], [CROSSREF], [CSA]
- Kim J. S., Pirnia F., Choi Y. H., Nguyen P. M., Knepper B., et al. Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint. Oncogene 2000; 19: 6082–6090, [INFOTRIEVE], [CROSSREF], [CSA]
- Maksumova L., Ohnishi K., Muratkhodjaev F., Zhang W., Pan L., et al. Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin. Leukemia 2000; 14: 1444–1450, [INFOTRIEVE], [CROSSREF], [CSA]
- Iishi H., Tatsuta M., Baba M., Yano H., Sakai N., et al. Ras p21 Isoprenylation inhibition induces flat colon tumors in Wistar rats. Dis. Colon Rectum 2000; 43: 70–75, [INFOTRIEVE], [CROSSREF], [CSA]
- Schmidt F., Groscurth P., Kermer M., Dichgans J., Weller M. Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells. Acta Neuropathol. 2001; 101: 217–224, [INFOTRIEVE], [CSA]
- Wong W. W., Tan M. M., Xia Z., Dimitroulakos J., Minden M. D., et al. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin. Cancer Res. 2001; 7: 2067–2075, [INFOTRIEVE], [CSA]
- Murakami M., Goto T., Saito Y., Goto S., Kochi M., et al. The inhibitory effect of simvastatin on growth in malignant gliomas–with special reference to its local application with fibrin glue spray in vivo. Int. J. Oncol. 2001; 19: 525–531, [INFOTRIEVE], [CSA]
- Dimitroulakos J., Ye L. Y., Benzaquen M., Moore M. J., Kamel-Reid S., et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin. Cancer Res. 2001; 7: 158–167, [INFOTRIEVE], [CSA]
- Wong W. W., Dimitroulakos J., Minden M. D., Penn L. Z. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002; 16: 508–519, [INFOTRIEVE], [CROSSREF], [CSA]
- van de Donk N. W., Kamphuis M. M., Lokhorst H. M., Bloem A. C. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002; 16: 1362–1371, [INFOTRIEVE], [CROSSREF], [CSA]
- Kusama T., Mukai M., Iwasaki T., Tatsuta M., Matsumoto Y., et al. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002; 122: 308–317, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wang C. Y., Zhong W. B., Chang T. C., Lai S. M., Tsai Y. F. Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 2003; 88: 3021–3026, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Shibata M. A., Kavanaugh C., Shibata E., Abe H., Nguyen P., et al. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 2003; 24: 453–459, [INFOTRIEVE], [CROSSREF], [CSA]
- Seeger H., Wallwiener D., Mueck A. O. Statins can inhibit proliferation of human breast cancer cells in vitro. Exp. Clin. Endocrinol. Diabetes 2003; 111: 47–48, [INFOTRIEVE], [CROSSREF], [CSA]
- Denoyelle C., Albanese P., Uzan G., Hong L., Vannier J. P., et al. Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell Signal. 2003; 15: 327–338, [INFOTRIEVE], [CROSSREF], [CSA]
- Collisson E. A., Kleer C., Wu M., De A., Gambhir S. S., et al. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol. Cancer Ther. 2003; 2: 941–948, [INFOTRIEVE], [CSA]
- Paragh G., Kertai P., Kovacs P., Paragh G., Jr., Fulop P., et al. HMG CoA reductase inhibitor fluvastatin arrests the development of implanted hepatocarcinoma in rats. Anticancer Res. 2003; 23: 3949–3954, [INFOTRIEVE], [CSA]
- Koyuturk M., Ersoz M., Altiok N. Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase. Neurosci. Lett. 2004; 370: 212–217, [INFOTRIEVE], [CROSSREF], [CSA]
- Werner M., Sacher J., Hohenegger M. Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells. Br. J. Pharmacol. 2004; 143: 715–724, [INFOTRIEVE], [CROSSREF], [CSA]
- Gronich N., Drucker L., Shapiro H., Radnay J., Yarkoni S., et al. Simvastatin induces death of multiple myeloma cell lines. J. Investig. Med. 2004; 52: 335–344, [INFOTRIEVE], [CSA]
- Muck A. O., Seeger H., Wallwiener D. Inhibitory effect of statins on the proliferation of human breast cancer cells. Int. J. Clin. Pharmacol. Ther. 2004; 42: 695–700, [INFOTRIEVE], [CSA]
- Horiguchi A., Sumitomo M., Asakuma J., Asano T., Asano T., et al. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin. Cancer Res. 2004; 10: 8648–8655, [INFOTRIEVE], [CROSSREF], [CSA]
- Wu J., Wong W. W., Khosravi F., Minden M. D., Penn L. Z. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res. 2004; 64: 6461–6468, [INFOTRIEVE], [CROSSREF], [CSA]
- Shibata M. A., Ito Y., Morimoto J., Otsuki Y. Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial–mediated apoptotic mechanism. Carcinogenesis 2004; 25: 1887–1898, [INFOTRIEVE], [CROSSREF], [CSA]
- Cafforio P., Dammacco F., Gernone A., Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005; 26: 883–891, [INFOTRIEVE], [CROSSREF], [CSA]
- Shellman Y. G., Ribble D., Miller L., Gendall J., Vanbuskirk K., et al. Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res. 2005; 15: 83–89, [INFOTRIEVE], [CROSSREF], [CSA]
- Cohen J. I. HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma. Br. J. Cancer 2005; 92: 1593–1598, [INFOTRIEVE], [CROSSREF], [CSA]
- Paragh G., Foris G., Paragh G., Jr., Seres I., Karanyi Z., et al. Different anticancer effects of fluvastatin on primary hepatocellular tumors and metastases in rats. Cancer Lett. 2005; 222: 17–22, [INFOTRIEVE], [CSA]
- Thibault A., Samid D., Tompkins A. C., Figg W. D., Cooper M. R., et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin. Cancer Res. 1996; 2: 483–491, [INFOTRIEVE], [CSA]
- Negre-Aminou P., van Vliet A. K., van Erck M., van Thiel G. C., van Leeuwen R. E., et al. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim. Biophys. Acta 1997; 1345: 259–268, [INFOTRIEVE], [CSA]
- Mueck A. O., Seeger H., Wallwiener D. Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause 2003; 10: 332–336, [INFOTRIEVE], [CROSSREF], [CSA]
- Harwood H. J., Jr., Bridge D. M., Stacpoole P. W. In vivo regulation of human mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase. Studies in normal subjects. J. Clin. Invest. 1987; 79: 1125–1132, [INFOTRIEVE], [CSA]
- Downs J. R., Clearfield M., Tyroler H. A., Whitney E. J., Kruyer W., et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am. J. Cardiol. 2001; 87: 1074–1079, [INFOTRIEVE], [CROSSREF], [CSA]
- Hebert P. R., Gaziano J. M., Chan K. S., Hennekens C. H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278: 313–321, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bjerre L. M., LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am. J. Med. 2001; 110: 716–723, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pfeffer M. A., Keech A., Sacks F. M., Cobbe S. M., Tonkin A., et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002; 105: 2341–2346, [INFOTRIEVE], [CROSSREF], [CSA]
- Baigent C., Keech A., Kearney P. M., Blackwell L., Buck G., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–1278, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Setoguchi S., Avorn J., Schneeweiss S. Statins and the risk of colorectal cancer. N. Engl. J. Med. 2005; 353: 952–954, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Maisonneuve P., Lowenfels A. B. Statins and the risk of colorectal cancer. N. Engl. J. Med. 2005; 353: 952–954, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Benner J. S., Glynn R. J., Mogun H., Neumann P. J., Weinstein M. C., et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455–461, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Etminan M., Coogan P. F., Rosenberg L. Statins and cancer: will we ever know the answer?. Epidemiology 2002; 13: 607–608, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Thomsen R. W., Johnsen S. P., Olesen A. V., Mortensen J. T., Bøggild H., et al. Socioeconomic gradient in use of statins among Danish Patients: population-based cross-sectional study. Br. J. Pharmacol. 2005, [CSA]
- Larner J., Jane J., Laws E., Packer R., Myers C., et al. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am. J. Clin. Oncol. 1998; 21: 579–583, [INFOTRIEVE], [CROSSREF], [CSA]
- Lopez-Aguilar E., Sepulveda-Vildosola A. C., Rivera-Marquez H., Cerecedo-Diaz F., Valdez-Sanchez M., et al. Security and maximal tolerated doses of fluvastatin in pediatric cancer patients. Arch. Med. Res. 1999; 30: 128–131, [INFOTRIEVE], [CROSSREF], [CSA]
- Kim W. S., Kim M. M., Choi H. J., Yoon S. S., Lee M. H., et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest. New Drugs 2001; 19: 81–83, [INFOTRIEVE], [CROSSREF], [CSA]
- Kawata S., Yamasaki E., Nagase T., Inui Y., Ito N., et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer 2001; 84: 886–891, [INFOTRIEVE], [CROSSREF], [CSA]
- Knox J. J., Siu L. L., Chen E., Dimitroulakos J., Kamel-Reid S., et al. A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur. J. Cancer 2005; 41: 523–530, [INFOTRIEVE], [CROSSREF], [CSA]
- Wei J. T., Mott L. A., Baron J. A., Sandler R. S. Reported use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors was not associated with reduced recurrence of colorectal adenomas. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 1026–1027, [INFOTRIEVE], [CROSSREF], [CSA]
- Feleszko W., Zagozdzon R., Golab J., Jakobisiak M. Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice. Eur. J. Cancer 1998; 34: 406–411, [INFOTRIEVE], [CROSSREF], [CSA]
- Agarwal B., Bhendwal S., Halmos B., Moss S. F., Ramey W. G., et al. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin. Cancer Res. 1999; 5: 2223–2229, [PUBMED], [INFOTRIEVE], [CSA]
- Feleszko W., Jakobisiak M. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin. Cancer Res. 2000; 6: 1198–1199, [PUBMED], [INFOTRIEVE], [CSA]
- Holstein S. A., Hohl R. J. Interaction of cytosine arabinoside and lovastatin in human leukemia cells. Leuk. Res. 2001; 25: 651–660, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lishner M., Bar-Sef A., Elis A., Fabian I. Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J. Investig. Med. 2001; 49: 319–324, [INFOTRIEVE], [CSA]
- Soma M. R., Pagliarini P., Butti G., Paoletti R., Paoletti P., et al. Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N′-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells. Cancer Res. 1992; 52: 4348–4355, [INFOTRIEVE], [CSA]
- Wang W., Collie-Duguid E., Cassidy J. Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. FEBS Lett. 2002; 531: 415–420, [INFOTRIEVE], [CROSSREF], [CSA]
- Kozar K., Kaminski R., Legat M., Kopec M., Nowis D., et al. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int. J. Oncol. 2004; 24: 1149–1157, [INFOTRIEVE], [CSA]
- Rozados V. R., Hinrichsen L. I., McDonnell J., Scharovsky O. G. Lovastatin enhances in vitro radiation-induced apoptosis of rat B-cell lymphoma cells. J. Exp. Clin. Cancer Res. 2005; 24: 55–61, [INFOTRIEVE], [CSA]
- Agarwal B., Rao C. V., Bhendwal S., Ramey W. R., Shirin H., et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 1999; 117: 838–847, [INFOTRIEVE], [CROSSREF], [CSA]
- Feleszko W., Jalili A., Olszewska D., Mlynarczuk I., Grzela T., et al. Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. Oncol. Rep. 2002; 9: 879–885, [INFOTRIEVE], [CSA]
- Swamy M. V., Cooma I., Reddy B. S., Rao C. V., Lamin B. Caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens. Int. J. Oncol. 2002; 20: 753–759, [INFOTRIEVE], [CSA]
- Jalving M., Koornstra J. J., De Jong S., De Vries E. G., Kleibeuker J. H. Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. Aliment. Pharmacol. Ther. 2005; 21: 321–339, [INFOTRIEVE], [CROSSREF], [CSA]
- Moyad M. A. Heart healthy equals prostate healthy equals statins: the next cancer chemoprevention trial. Part I. Curr. Opin. Urol. 2005; 15: 1–6, [INFOTRIEVE], [CROSSREF], [CSA]
- Zielinski S. L. Following positive epidemiologic studies, statins to enter clinical trials for cancer prevention. J. Natl. Cancer Inst. 2005; 97: 1172–1173, [INFOTRIEVE], [CSA]